Bayer AG shares surged higher on Tuesday this week on news that the German company forecast its peak sale of pharmaceuticals to €12 billion.
Bayer forecast that its thrombosis treatment asundexian could bring in more than €5 billion. Revenue from the prostrate-cancer drug Nubeqa and cardio-renal therapy drug was set to both exceed €3 billion.
Does this mean that Bayer can rely on these medicines as drivers for growth over the coming years?
Is a short term run higher worth exploring for Bayer? The seasonal over the last 10 years have been promising seeing 8 gains in 10 years with an average return of 3%.
The maximum gain has been a steady 12.27% in 2015 and the maximum loss has been a relatively modest -1.57%.
So, is now the time to buy Bayer?
Major Trade Risks:
The major trade risk here is that bad news impacts the wider stock market and prior seasonal are no guarantee for future years performance.
Don’t just trade it, but Seasonax it